Patents by Inventor Bohdan Wasylyk

Bohdan Wasylyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSIS OF PROSTATE CANCER
    Publication number: 20110165178
    Abstract: The present invention relates to vitro diagnosis methods of prostate cancer from a test biological sample, comprising measuring the expression level of KIAA0153 in said test biological sample, as well as to methods for screening compounds inhibiting KIAA0153 gene expression or biological activity and uses of such KIAA0153 inhibiting compounds.
    Type: Application
    Filed: January 23, 2008
    Publication date: July 7, 2011
    Inventors: Bohdan Wasylyk, Alberto Zambrano, Joseph Abecassis, Helmut Klocker, Jack A. Schalken
  • Net, a transcription factor of the TCF family, as regulator of angiogenic factor expression
    Patent number: 7537887
    Abstract: The present invention relates to the regulation of the activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity. The invention further relates to methods of screening for agonists or antagonists of NET in order to identify new pro-angiogenic or anti-angiogenic compounds and to therapeutic uses of these compounds. The invention also relates to transgenic animals bearing mutations in NET gene.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: May 26, 2009
    Assignees: Aventis Pharma S.A., Institut National de la Sante de la Recherche Medicale
    Inventors: Bohdan Wasylyk, Marie-Christine Multon, Abdelkader Ayadi, Hong Zheng
  • Antagonist of the oncogenic activity of the protein MDM2, and use thereof in the treatment of cancers
    Publication number: 20080311608
    Abstract: The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.
    Type: Application
    Filed: January 10, 2007
    Publication date: December 18, 2008
    Inventors: Bruno Tocque, Bohdan Wasylyk, Marie-Christine Dubs-Poterszman
  • Antagonists of the oncogenic activity of the MDM2, and use thereof in the treatment of cancers
    Publication number: 20040209834
    Abstract: The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.
    Type: Application
    Filed: December 1, 2003
    Publication date: October 21, 2004
    Inventors: Bruno Tocque, Bohdan Wasylyk, Marie-Christine Dubs-Poterszman
  • Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
    Publication number: 20040053833
    Abstract: The present invention relates to the regulation of the activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity. The invention further relates to methods of screening for agonists or antagonists of NET in order to identify new pro-angiogenic or anti-angiogenic compounds and to therapeutic uses of these compounds. The invention also relates to transgenic animals bearing mutations in NET gene.
    Type: Application
    Filed: October 3, 2003
    Publication date: March 18, 2004
    Inventors: Bohdan Wasylyk, Marie-Christine Multon, Abdelkader Ayadi, Hong Zheng
  • ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE PROTEIN MDM2, AND USE THEREOF IN THE TREATMENT OF CANCERS
    Publication number: 20030060432
    Abstract: The present invention relates to the utilization of a compound capable of antagonizing at least partially the oncogenic activity of the protein Mdm2 for the preparation of a pharmaceutical composition intended more particularly to a treatment of cancers with no p53 context. It further relates to the viral vector comprising a nucleic acid sequence coding for a compound capable of inhibiting at least partially the oncogenic activity of the protein Mdm2, and to a corresponding pharmaceutical composition.
    Type: Application
    Filed: March 23, 1998
    Publication date: March 27, 2003
    Inventors: BRUNO TOCQUE, BOHDAN WASYLYK, MARIE-CHRISTINE DUBS-POTERSZMAN
  • Transgenic animals overexpressing MDM2
    Patent number: 6028245
    Abstract: The present invention relates to transgenic, non-human animals overexpressing a MDM2 gene. These animals model MDM2 over-expression associated with human tumors, display a major phenotype characterized by the severe skin disorder ichthyosis, and are useful for identifying compounds for the treatment of human disease. Therefore, the invention also relates to methods of using the animals for identifying compounds effective for the treatment of diseases of the skin and respiratory tract, and to the compounds themselves.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: February 22, 2000
    Assignees: Rhone-Poulenc Rorer SA, Institut National de la Sante et de la Recherche Medicale
    Inventors: Bohdan Wasylyk, Bruno Tocque, Moussa Alkhalaf